New drug combo aims to fight Hard-to-Treat sarcomas
NCT ID NCT04668300
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tests whether two immunotherapy drugs, oleclumab and durvalumab, can help people with sarcoma that has come back, spread, or stopped responding to treatment. About 75 adults and some teens (age 12+) with angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma will receive these drugs to see if they shrink tumors or slow the cancer. The goal is to find a new option for these rare and aggressive cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.